Member Info for Riesgo

Another who cannot argue from a risk and ethical perspective.

I don’t find it a monstrously ignorant comment and my wife died from a combination of cancer and chemotherapy. I would have happily stepped forward to take experimental shots so my wife could too. I wish they could stop *****footing around and start saving many lives soon.

I hope my fund managers maintain a healthy dose of FUD. It’s good for my wealth.

Not everyone has forgotten that ‘we can sell as many LFTs as we can make, Affimers can be quickly adapted to detect mutations, much quicker than antibodies and then oops we’ve been using the wrong antibody.

There wasn’t. So unless ‘pre-clinical’ isn’t discussed during the Science Day it looks like another RNS is due over the next 10 days. Only 10 days left to buy.

We had an update last month, after we we knew about the Science Day. Could that have been the update referred to? I hope not.

Perhaps we’ve already had all we are going to get.
“ The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day “

“Science Day to include presentation of the data emerging from the phase 1a clinical trial of AVA6000”

I anyone wants to buy in at a good price, then the sooner the better seems obvious.

“ The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day “

Before Science Day
https://avacta.com/avacta-to-host-therapeutics-division-science-day-on-23rd-february-2023/

I feel the emphasis has changed a little. RP2D used to carry equal emphasis to MTD, which I understood would be useful if MTD could not be determined. And with precision making the toxin safer I understand why RP2D maybe preferrable.

We are supposed to hear of price sensitive information in an RNS rather than second hand via the Science Day.
The last RNS mentioned Dox in tumours has been observed at therapeutic levels. I read this as shrinking the tumour.

This may useful
https://beta.clinicaltrials.gov/study/NCT04969835?distance=50&term=Ava6000&rank=1&fbclid=IwAR388PwJDt-VK8eUKvleVZHxfGHjuASlAq78_dQcZpbjk2cLwpf1HkcDDKo&fs=e&s=cl

Vert, does it matter to Avacta where the money comes from? Oversubscribed is still oversubscribed isn’t it?

The letter may be making a general point about funding for U.K. innovation. A bit of a contradiction because Avacta finds fund raising easy. Oversubscribed etc.

You manage to sound so wound up, even when we agree. Chillax.

It seems unethical not to roll out AV6k asap. FDA just need time to agree.

Wyn, keep it up. Good fun watching you stick it back to the abusive bully boys.

On a separate subject do you think the emphasis has shifted away from RP2D to MTD.

It also reads like they need to decide on which tumours to include. So narrower. Which ones are left out must be a difficult decision.

https://beta.clinicaltrials.gov/study/NCT04969835?distance=50&term=Ava6000&rank=1&fbclid=IwAR2zhqu08YeStyGFkir3Vp76YQkyNdLOkfMTGJEX2i8LnLhrtM2HaxxpMqs&fs=e&s=cl